Future Directions in ALK-Positive and BRAF-Positive NSCLC Management

, , ,

Peer Exchange | <b>Latest Advances in ALK-Positive and BRAF-Positive V600E NSCLC: Efficacy Updates, Brain Metastases Management, and Optimal Treatment Sequencing </b>

Panelists discuss how advancements in targeted therapies and personalized medicine are crucial for addressing the pressing unanswered questions in the management of ALK-positive and BRAF-positive cancers.

  1. Dr Bestvina: What are the most pressing unanswered questions in ALK-positive and BRAF-positive management?
  2. How do you envision the treatment landscape evolving over the next 5 years?

Related Content:

Precision BRAF Therapy: Optimizing Dosing, Sequencing, and Toxicity Management in NSCLC
Long-Term Outcomes of BRAF-MEK Inhibitor Combinations
Combination Therapies in BRAF-Positive NSCLC